DETAILED ACTION
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Restriction/Election Requirement
The Office acknowledges the Applicant’s election of Group I (directed to X = B or Al) as set forth in the Requirement for Restriction/Election filed 05/07/26 in the Response filed 06/10/26.
The election reads on Claims 1-12.
Claims 1-12 are pending. No claims have been withdrawn from consideration.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1 and 4-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kang et al. (KR 10-2020-0087717).
Examiner’s Note: The Office has relied on the Machine English translation of foreign document publication KR 10-2020-0087717 (herein referred to as “Kang et al”) as the English equivalent. Unless otherwise noted, all figure, page, and paragraph numbers referenced herein refer to numbers found in the Machine English translation.
Kang et al. discloses the following compound:
PNG
media_image1.png
122
104
media_image1.png
Greyscale
(page 37 of Kang et al.) such that A3 = substituted C6 aromatic hydrocarbon (substituted benzene wherein substituent = Applicant’s Structural Formula A), A1 = substituted C6 aromatic hydrocarbon (substituted benzene wherein substituent = t-butyl), A2 = substituted C12 heterocyclic ring, Y1 = S, and Y2 = NR1 (with R1 = substituted C12 aryl (substituted biphenyl)) of Applicant’s Formula I. Kang et al. discloses an organic electroluminescent (EL) device comprising the following layers: anode, hole-injecting layer, hole-transporting layer, light-emitting layer, hole-blocking layer, electron-transporting layer, electron-injecting layer, and cathode for the construction of displays ([0004], [0195]); such layers are formed via solution methods such as spin coating ([0171]). Kang et al. discloses its inventive compounds as dopant materials in the light-emitting layer which are combined with the following host material ([0209], [0211]):
PNG
media_image2.png
108
74
media_image2.png
Greyscale
(page 39 of Kang et al.) such that R11-18 = hydrogen, n = 0, Ar2 = Ar4 = hydrogen, Ar1 = unsubstituted C6 arylene (phenyl), and Ar3 = substituted C10 arylene (substituted naphthyl) of Applicant’s Formula H. Kang et al. discloses the presence of additional dopant and/or host materials in the light-emitting layer ([0209], [0211]).
Allowable Subject Matter
8. Claims 2 and 3 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Examiner’s Note: The Office has relied on the Machine English translation of foreign document publication KR 10-2020-0087717 (herein referred to as “Kang et al”) as the English equivalent. Unless otherwise noted, all figure, page, and paragraph numbers referenced herein refer to numbers found in the Machine English translation.
Kang et al. discloses compounds of the following form:
PNG
media_image3.png
202
284
media_image3.png
Greyscale
([0010]); an embodiment is disclosed:
PNG
media_image1.png
122
104
media_image1.png
Greyscale
(page 37 of Kang et al.). However, it is the position of the Office that neither Kang et al. singly nor in combination with any other prior art discloses any of the compounds as recited in the claims, particularly in regards to the nature of A1-3 of Formula I.
Conclusion
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAY L YANG whose telephone number is (571)270-1137. The examiner can normally be reached Mon-Fri, 6am-3pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer A Boyd can be reached at 571-272-7783. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JAY YANG/Primary Examiner, Art Unit 1786
Prosecution Insights